Tuesday, May 1, 2012

Gilead strikes deal with antibody drug technology company AnaptysBio

Gilead Sciences Inc. will use technology from AnaptysBio Inc. to develop new antibody drug leads. Gilead (NASDAQ: GILD) made an upfront payment, according to AnaptysBio, a privately held company in San Diego, and will provide research funding to AnaptysBio. Specific figures were not disclosed by AnaptysBio, and the company didn’t say which disease areas Foster City-based Gilead would target with the technology.

No comments:

Post a Comment